Abstract
Great strides have been made towards the control of poliomyelitis since the introduction of the two poliovaccines – inactivated poliovirus vaccine (IPV), which was licensed in the United States in 1954, and live attenuated oral poliovaccine (OPV), in 1961. Today a large majority of physicians and other health–care workers in industrialized countries never see a patient with paralytic poliomyelitis. Unfortunately, this is far from the situation in many developing countries, particularly in tropical and subtropical climates, where hundreds of thousands of children still become paralysed victims, year in and year out.